Methods In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placebo, along with lifestyle intervention, for 68 weeks
This positions semaglutide GLP-1 as a compelling option for those struggling with obesity or overweight conditions
It promotes differentiation in a crowded market and supports sustained brand loyalty
Understanding your genetic and biomarker context allows you to partner more effectively with your provider in managing fatigue
The platinum standard of purity
Both GABA and serotonin availability declined with reduced receptor expression for GABA A 2 and GABAB1 in prefrontal cortex in the 2 week CMS (Tyagi et al., 2025)